Antibody engineering
Design and screen antibodies before synthesis
An antibody engineering platform to design antibodies and nanobodies, model their structures, and review humanness and developability before synthesis.
Trusted by 16,500+ researchers and published in
Prepare antigens and epitopes
Antibody design starts from a clean antigen. Repair the structure, check protonation and surface exposure, and find the patches most likely to work as epitopes.
Design antibodies and nanobodies
Generate antibody, Fab and nanobody candidates with several design methods. Each one keeps its own native ranking, so you can see where the methods agree.
Model antibodies and review binding
Build structures for your candidates, check their geometry, and score the antibody-antigen interface so weak binders are caught before synthesis.
Screen sequences for developability
Number the variable regions, then check humanness, solubility and viscosity. Aggregation and high viscosity are far cheaper to find here than after expression.
Antibody engineering use cases
Pick the method that fits your question and evidence. Each one comes with a workflow you can open and edit.
Antibody design
Generate and redesign antibodies or nanobodies with antigen, framework, CDR, structure, and developability context.
Antibody structure prediction
Predict antibody variable-domain structures from paired chains and examine framework, CDR-loop, and residue-level confidence.
Antibody–antigen docking
Explore antibody–antigen binding orientations using structural models and available epitope or paratope evidence.
Protein complex structure prediction
Predict multi-chain protein assemblies and compare interface geometry, stoichiometry assumptions, confidence, and model agreement.
Guides for antibody engineering
Background guides on the methods, scores, and numbers behind these workflows.

Antibodies · 15 min
What is antibody engineering?
Antibody engineering changes an antibody's sequence or structure to improve binding, reduce immunogenicity, tune effector function or create new formats. Learn the core techniques and computational workflows.

Antibodies · 13 min
Antibody variable regions: VH, VL, CDRs and frameworks
VH and VL domains, the six CDRs and eight framework regions they contain, how Kabat, Chothia and IMGT draw CDR boundaries, and how V(D)J recombination and somatic hypermutation create variable-region diversity.

Antibodies · 7 min
What is Chai-2? De novo antibody design explained
Understand what Chai-2 designs, what its experimental hit rates mean, how access works, and which open tools address related antibody and protein binder tasks.

Antibodies · 12 min
Human vs humanized vs chimeric antibodies: the origin of every FDA-approved antibody
Of 159 antibody products the FDA licensed by September 2026, 52% are humanized, 34% fully human, 9% chimeric and 5% murine, by ProteinIQ's label-by-label count. The fully human share has held near one-third since 2015. Free CSV.

Antibodies · 11 min
mBER and ColabDesign metrics explained
What esm_score, i_ptm, i_pae, plddt, ptm, pae and seq_ent mean in mBER and ColabDesign output, which direction is better, and the cutoffs the mBER authors, BindCraft and other studies use.

Structures · 17 min
ipSAE explained
ipSAE is an interface confidence score for AlphaFold2, AlphaFold3 and Boltz that ignores disordered tails. Learn how it is calculated, why it beats ipTM and what 0.6 to 0.8 mean.
FAQs
ProteinIQ connects those complementary analyses without separating the evidence from the candidate. Researchers can annotate heavy and light chains, assess humanness and sequence liabilities, generate or inspect structures, and compare docking or design outputs alongside the original inputs. Begin with an antigen, antibody sequence, framework, or candidate set and choose a focused tool or workflow. Each run preserves the resulting tables, residue annotations, structures, confidence values, logs, and downloadable files for a traceable synthesis shortlist.
The computational stages that come before synthesis: prepare the antigen, generate or collect antibody and nanobody candidates, model their structures, then number the sequences and review humanness and developability. The workflow ends with a ranked shortlist and its provenance. ProteinIQ does not cover expression, purification, or assay work, which happen in the lab afterwards.
ProteinIQ hosts RFantibody, BoltzGen, IgGM, and mBER for generating antibodies, Fabs, and nanobodies against an antigen structure, plus AntiFold, DiffAb, and IgDesign for redesigning an existing antibody. No single method suits every project, so the starting point decides: a target alone, a framework, or an existing complex. Running several generators from the same antigen and applying the same checks to each makes their outputs comparable.
Yes. ABodyBuilder3 and ImmuneBuilder run in the browser from heavy and light chain sequences, and ImmuneBuilder also models nanobodies. Each returns a PDB structure with confidence values, and no local installation or GPU is needed.
ProteinIQ supports antibody engineering workflows for numbering, germline context, humanness review, humanization triage, developability screening, antibody structure prediction, nanobody modeling, antibody-antigen docking, and design review. Each workflow keeps upstream scores, files, and tool conventions visible for scientific inspection.
ProteinIQ antibody tools can accept FASTA sequences, paired heavy and light chains, single-domain or nanobody sequences, PDB structures, and antigen structures depending on the upstream model. The platform keeps each accepted input format tied to the tool that produced the downstream annotation, model, or score.
Yes. ProteinIQ can run antibody humanization and humanness review workflows using tools such as BioPhi, AbLang-style language model review, and humanization comparison steps. The answers are presented as sequence-level evidence for review, not as a hidden replacement for expert antibody engineering judgment.
Yes. ProteinIQ includes antibody and nanobody structure workflows that can turn variable-region sequences into modeled structures when the selected upstream tool supports that input. The generated PDB or related structure files, confidence values, and logs remain available for inspection and export.
Yes. ProteinIQ supports antibody-antigen docking and exploratory complex modeling workflows that can combine antibody chains or modeled antibody structures with an antigen structure. Docking outputs are useful for hypothesis generation and triage, while binding, specificity, and epitope claims still need experimental evidence.
ProteinIQ keeps antibody numbering, germline calls, humanness scores, developability tables, modeled structures, docking files, and logs associated with the input sequence or structure that produced them. This helps reviewers avoid separating heavy chains, light chains, residue annotations, and downstream models during triage.
Yes. ProteinIQ workflows are useful when you want connected antibody annotation, humanization, structure, and docking steps, but individual tools such as ANARCI, BioPhi, ImmuneBuilder, RFantibody, ParaSurf, and LightDock can also be opened directly for focused analysis.
ProteinIQ antibody workflows can export numbered sequence tables, humanness and developability CSV files, predicted structures, designed sequences, docking models, logs, and upstream result files depending on the tool. Exported outputs preserve the upstream labels and formats needed for review outside the platform.
No. ProteinIQ organizes computational antibody engineering evidence for prioritization and review. Expression, binding, specificity, immunogenicity, developability, and manufacturability experiments are still required before making biological, therapeutic, or clinical claims.
AI answers from our docs. No sign-in needed.
Focus on research, not infrastructure
Start free with 200 credits a month and no installs. Upgrade when your project needs more compute.